Cambridge-based Raze Therapeutics announced its launch Monday, adding that it has closed on a $24 million Series A financing.
Investors in the Series A financing include Atlas Venture, MPM Capital Management, MS Ventures, Partners Innovation Fund, Astellas Venture Management, and Novartis, the Raze press release said.
Atlas partner Jason Rhodes is Raze’s acting chief executive.
Raze seeks to develop treatments that fight cancer by targeting mitochondrial one-carbon metabolism – fundamental metabolic pathways necessary for tumors to grow and survive.
“Aberrant growth and the accumulation of biomass are hallmarks of cancer,” Rhodes said in a statement. “Raze targets newly identified pathways that are essential to this anabolic metabolism and tumor survival. We have created a powerful drug discovery platform and are rapidly advancing programs directed to solid tumors and hematological malignancies.”
In its press release, Raze said its proprietary platform is based on discoveries by its scientific founders, Vamsi Mootha, MD, of Massachusetts General Hospital; Joshua Rabinowitz, MD, of Princeton; and David Sabatini, MD, PhD, of the Whitehead Institute.